Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
IRVING, Texas, June 04, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa Hakko Kirin Co., Ltd....
-
IRVING, Texas, June 01, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that Chief Development Officer, Keith Ward,...
-
IRVING, Texas, May 31, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted...
-
Interim Data Demonstrate Significant Improvement in Kidney Function in Both Diseases Conference Call With Management Scheduled Today, May 25, 2018 at 8:00am ET IRVING, Texas, May 25, 2018 (GLOBE...
-
CATALYST TRIAL IN CTD-PAH FINAL SAMPLE SIZE SET AT 200; TOP-LINE DATA EXPECTED IN THE FIRST HALF OF 2020 PHOENIX TRIAL INTERIM DATA FOR ADPKD AND IGA NEPHROPATHY COHORTS AT ERA-EDTA IN MAY; FULL DATA...
-
IRVING, Texas, April 24, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced new preclinical data...
-
Bardoxolone Treatment Produced Significant Increase in Kidney Function Maintained Through Week 36 Conference Call With Management Scheduled Thursday, April 12th at 8:30am ET IRVING, Texas, April ...
-
Novel, Orally-Bioavailable Agent With Potent Activity in Cell-Based and Animal Models Non-Human Primate Proof-of-Concept for Suppression of IL-17A Achieved Phase 1 Initiation for RTA 1701...
-
IRVING, Texas, March 29, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa...
-
Significant Improvement in 6MWD in Patients With IPF and Sarcoidosis No Safety Signals Identified IRVING, Texas, March 22, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA)...